Jens Huober

33.1k total citations · 4 hit papers
321 papers, 12.1k citations indexed

About

Jens Huober is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jens Huober has authored 321 papers receiving a total of 12.1k indexed citations (citations by other indexed papers that have themselves been cited), including 250 papers in Oncology, 175 papers in Cancer Research and 114 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jens Huober's work include Breast Cancer Treatment Studies (149 papers), HER2/EGFR in Cancer Research (109 papers) and Cancer Treatment and Pharmacology (98 papers). Jens Huober is often cited by papers focused on Breast Cancer Treatment Studies (149 papers), HER2/EGFR in Cancer Research (109 papers) and Cancer Treatment and Pharmacology (98 papers). Jens Huober collaborates with scholars based in Germany, Switzerland and United States. Jens Huober's co-authors include Sibylle Loibl, Gϋnter von Minckwitz, Michael Untch, Christian Jackisch, Holger Eidtmann, J. Hilfrich, Jens‐Uwe Blohmer, Carsten Denkert, Peter A. Fasching and Bernd Gerber and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jens Huober

311 papers receiving 11.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. Journal of Clinical Oncology profile →
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

2017 1.1k citations Matthew P. Goetz, Masakazu Toi et al. Journal of Clinical Oncology profile →
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial

2018 516 citations Sibylle Loibl, Joyce O’Shaughnessy et al. profile →
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Jens Huober	8.6k	6.0k	3.3k	1.9k	1.7k	321	12.1k
Christian Jackisch	8.5k 1.0×	6.2k 1.0×	1.8k 0.6×	2.2k 1.2×	1.8k 1.0×	356	12.6k
P. Fumoleau	9.6k 1.1×	4.4k 0.7×	2.7k 0.8×	1.1k 0.6×	3.3k 1.9×	326	14.3k
Elżbieta Senkus	6.2k 0.7×	4.0k 0.7×	2.5k 0.8×	1.2k 0.6×	2.3k 1.4×	113	10.1k
Angelo Di Leo	9.9k 1.2×	5.2k 0.9×	4.5k 1.4×	702 0.4×	4.1k 2.4×	313	14.4k
Charles E. Geyer	11.3k 1.3×	8.6k 1.4×	3.2k 1.0×	2.9k 1.6×	2.5k 1.5×	183	16.3k
Semiglazov Vf	8.5k 1.0×	5.6k 0.9×	2.1k 0.6×	1.5k 0.8×	2.1k 1.2×	239	11.9k
Young‐Hyuck Im	8.7k 1.0×	3.8k 0.6×	3.7k 1.1×	1.2k 0.7×	2.9k 1.7×	270	12.4k
Jennifer K. Litton	7.7k 0.9×	3.8k 0.6×	2.4k 0.7×	1.1k 0.6×	3.2k 1.8×	238	11.1k
Aňa Lluch	10.3k 1.2×	6.1k 1.0×	2.5k 0.7×	1.2k 0.6×	4.1k 2.4×	306	14.7k
Constance Cirrincione	6.8k 0.8×	4.7k 0.8×	1.6k 0.5×	1.6k 0.8×	1.3k 0.8×	81	9.8k

Countries citing papers authored by Jens Huober

Since Specialization

Citations

This map shows the geographic impact of Jens Huober's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jens Huober with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jens Huober more than expected).

Fields of papers citing papers by Jens Huober

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jens Huober. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jens Huober. The network helps show where Jens Huober may publish in the future.

Co-authorship network of co-authors of Jens Huober

This figure shows the co-authorship network connecting the top 25 collaborators of Jens Huober. A scholar is included among the top collaborators of Jens Huober based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jens Huober. Jens Huober is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goetz, Matthew P., İrfan Çiçin, Laura Testa, et al.. (2024). Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. npj Breast Cancer. 10(1). 34–34. 12 indexed citations

O’Shaughnessy, Joyce, Laura Testa, Sara M. Tolaney, et al.. (2023). 274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study. Annals of Oncology. 34. S293–S293. 1 indexed citations

Harbeck, Nadia, Priya Rastogi, J. O’Shaughnessy, et al.. (2023). LBA17 Adjuvant abemaciclib plus endocrine therapy for HR+, HER2-, high-risk early breast cancer: Results from a preplanned monarchE overall survival interim analysis, including 5-year efficacy outcomes. Annals of Oncology. 34. S1256–S1256. 11 indexed citations

Jarczok, Marc N., et al.. (2023). Enhancing coping skills through brief interventions during cancer therapy – a quasi-experimental clinical pilot study. Frontiers in Psychology. 14. 1253423–1253423. 1 indexed citations

Schmidt, Marcus, Ulrike Nitz, Toralf Reimer, et al.. (2023). Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate – The ICE randomized clinical trial. European Journal of Cancer. 194. 113324–113324. 1 indexed citations

Bekes, Inga & Jens Huober. (2023). Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives. Cancers. 15(16). 4190–4190. 11 indexed citations

Huebner, Hanna, Matthias Rübner, Andreas Schneeweiß, et al.. (2023). RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.. Journal of Clinical Oncology. 41(16_suppl). 1011–1011. 1 indexed citations

Wildiers, Hans, Anne Armstrong, Eveline Cuypere, et al.. (2023). Paclitaxel plus Eftilagimod Alpha, a Soluble LAG-3 Protein, in Metastatic, HR+ Breast Cancer: Results from AIPAC, a Randomized, Placebo Controlled Phase IIb Trial. Clinical Cancer Research. 30(3). 532–541. 12 indexed citations

Huober, Jens, Carlos H. Barrios, Naoki Niikura, et al.. (2022). Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Journal of Clinical Oncology. 40(25). 2946–2956. 82 indexed citations

10.

Johnston, Stephen, Joyce O’Shaughnessy, Miguel Martín, et al.. (2021). Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. npj Breast Cancer. 7(1). 80–80. 36 indexed citations

11.

Cosimo, Serena Di, Luca Porcu, Dominique Agbor‐Tarh, et al.. (2020). Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Research. 22(1). 115–115. 22 indexed citations

12.

Gregorio, Nikolaus de, Amelie de Gregorio, Florian Ebner, et al.. (2019). Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases. Archives of Gynecology and Obstetrics. 300(1). 161–168. 17 indexed citations

13.

Loibl, Sibylle, Karsten E. Weber, Jens Huober, et al.. (2018). Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research. 24(14). 3358–3365. 8 indexed citations

14.

Riethdorf, Sabine, Volkmar Müller, Sibylle Loibl, et al.. (2017). Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial. Clinical Cancer Research. 23(18). 5384–5393. 82 indexed citations

15.

Kümmel, Sherko, Stefan Paepke, Jens Huober, et al.. (2017). Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European Journal of Cancer. 84. 1–8. 17 indexed citations

16.

Baselga, José, Gail D. Lewis Phillips, Sunil Verma, et al.. (2016). Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer. Clinical Cancer Research. 22(15). 3755–3763. 150 indexed citations

17.

Loibl, Sibylle, Silvia Darb‐Esfahani, Jens Huober, et al.. (2016). Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research. 22(11). 2675–2683. 34 indexed citations

18.

Klauschen, Frederick, Stephan Wienert, Wolfgang Schmitt, et al.. (2014). Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study. Clinical Cancer Research. 21(16). 3651–3657. 78 indexed citations

19.

Minckwitz, Gϋnter von, Jens‐Uwe Blohmer, Serban Dan Costa, et al.. (2013). Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology. 31(29). 3623–3630. 265 indexed citations

20.

Moebus, Volker, Christian Jackisch, Hans-Joachim Lueck, et al.. (2010). Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III Study. Journal of Clinical Oncology. 28(17). 2874–2880. 126 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact